Press releaseBusiness Wire
Neurogene
NGNE · NASDAQ
$25.40+$1.23 (+5.09%)TodayMarket closed ·
Prev close $24.17
About NGNE
- Employees
- 131
- Headquarters
- New York City, New York
- Listed
- Mar 7, 2014
- Sector
- Health Care
- Industry
- Biotechnology
- Website
- neurogene.com
NGNE key statistics
- Market cap
- 508.29M
- Price-earnings ratio
- 0.00
- Dividend yield
- —
- Average volume
- 374.78K
- Volume
- 205.91K
- Open price
- $24.20
- High today
- $25.84
- Low today
- $23.80
- 52 Week high
- $43.66
- 52 Week low
- $15.93
Neurogene (NGNE) at a glance
As of Oct 20, 2026, Neurogene (NGNE) shares are priced at $25.40, giving the company a market cap of 508.29M and a price-to-earnings ratio of 0.00.
Today the stock has traded between $23.80 and $25.84. The current price is 6.7% above the day's low and 1.7% below its high.
Volume so far is 205.91K shares, below the average of 374.78K shares a day.
Over the past year Neurogene has ranged from $15.93 to $43.66, and now sits 34% of the way up that range.
Neurogene met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$1.53 per share against an estimate of -$1.45.
The average analyst price target is $82.04, 223.0% above the current price, from 5 recent ratings.
Analyst ratings
Latest rating from each analyst over the past 12 months
100%of 5 analyst ratings say Buy
- Buy100.0%
- Hold0.0%
- Sell0.0%
Price target · 9 analystsAvg $82.04
- Low
- $46.46
- Now
- $25.40
- High
- $174.30
NGNE earnings
Earnings per share, reported against the analyst estimate
Beat the estimate in 6 of the last 8 quarters, by 9.3% on average.
- Q3 FY24: reported -$1.19 per share against an estimate of -$1.25
- Q4 FY24: reported -$0.99 per share against an estimate of -$1.15
- Q1 FY25: reported -$1.08 per share against an estimate of -$1.08
- Q2 FY25: reported -$1.05 per share against an estimate of -$1.18
- Q3 FY25: reported -$0.99 per share against an estimate of -$1.27
- Q4 FY25: reported -$1.17 per share against an estimate of -$1.21
- Q1 FY26: reported -$1.39 per share against an estimate of -$1.32
- Q2 FY26: reported -$1.53 per share against an estimate of -$1.45
NGNE news
- Press releaseBusiness Wire
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Press releaseBusiness Wire
Neurogene to Participate in H.C. Wainwright 28th Annual Global Investment Conference
- Press releaseBusiness Wire
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Press releaseBusiness Wire
Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates
- Press releaseBusiness Wire
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Press releaseBusiness Wire
Newleos Names Rohan Palekar as Board Chairman
- Press releaseBusiness Wire
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Similar companies
Companies in the same industry as Neurogene
Most active stocks
Highest trading volume today
- EARIEntertainment Arts Research$0.0003−16.67%
- SEIISharing Economy International$0.0004+100.00%
- NWGLCL Workshop Group$0.1522+27.90%
- TMSHTrans Global Assets$0.0002+0.00%
- AEFIAmerican EcoFuels$0.0007+0.00%
- CBDW1606$0.0002+0.00%
- FITYFifty 1 Labs$0.0001−66.67%
- PRSOPeraso$0.5914+54.13%
- SDSTStardust Power$0.02−23.66%
- SHFSSHF Holdings$0.0899−4.36%
- FRTTFort Technology$0.7121+32.63%
- CBDLCBD Life Sciences$0.0002−25.00%
Newly listed
Companies that went public in the past six weeks
- TCXBTCGX Acquisition Corp. II$10.56+1.54%
- CTYCITY THERAPEUTICS$20.83−2.94%
- IAMIambic Therapeutics$16.01−2.02%
- AMROAmaero$5.68+1.25%
- FLSCFrazier Life Sciences Acquisition Corp. II$10.28−0.10%
- TRXBTRex Bio$14.44−2.43%
- RTSNRetension Pharmaceuticals$16.18−0.92%
- PAXGUPine Tree Acquisition$9.98+0.00%
- PORTUSouthport Acquisition Corp. IIListed Oct 1, 2026
- CHWMChilwa Minerals$5.18+3.39%
- ACCVAccelevation Holdings$12.31−1.44%
- RZAIROZE AI$10.28+1.28%
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.